d-环丝氨酸在耐多药结核中的药动学/药效学、敏感性与剂量启示:一项浮士德式交易
该研究通过系统检索未发现d-环丝氨酸的药动学/药效学研究,遂在结核中空纤维系统模型中开展暴露-效应与剂量分割实验,并测定415株临床结核分枝杆菌的MIC。结果显示疗效由%TMIC驱动,30%TMIC可达1.0 log10 CFU/mL杀灭;蒙特卡洛模拟提示750mg每日两次在肺空洞中达标率92%,500mg每日两次在脑膜炎中达标率85%,暂定敏感性折点为64 mg/L,但达标剂量可能神经毒性高。
要点
- d-环丝氨酸对结核分枝杆菌具有杀菌活性,疗效驱动指标为%TMIC。
- 暂定流行病学折点与临床敏感性折点均为64 mg/L。
- 肺空洞达标需750mg每日两次,脑膜炎达标需500mg每日两次。
核心结论
- d-环丝氨酸对结核分枝杆菌具有杀菌作用,敏感性折点为64 mg/L。
- 在患者中实现杀菌所需的剂量较高,且可能具有神经毒性。
研究设计与样本
- 系统检索d-环丝氨酸的药动学/药效学研究,未发现已发表研究。
- 在结核中空纤维系统模型中进行暴露-效应与剂量分割实验。
- 测定415株临床结核分枝杆菌分离株的d-环丝氨酸MIC。
- 利用包括空洞内浓度在内的结果,通过蒙特卡洛实验在10000例患者中确定可达标或超标的临床剂量。
主要发现
- 环丝氨酸在28天内杀灭6.3 log10 CFU/mL的细胞外杆菌。
- 疗效由浓度持续高于MIC的时间百分比(%TMIC)驱动,%TMIC=30%时可达1.0 log10 CFU/mL杀灭(目标暴露)。
- Sensititre MYCOTB法测定的暂定流行病学折点为64 mg/L。
- 蒙特卡洛实验中,750mg每日两次在92%患者的肺空洞中达标,500mg每日两次在85%脑膜炎患者中达标。
- 基于蒙特卡洛实验提出的临床敏感性折点为64 mg/L。
关键数值与推荐
- 目标暴露:%TMIC=30%对应1.0 log10 CFU/mL杀灭。
- 暂定流行病学折点(Sensititre MYCOTB法)为64 mg/L。
- 肺空洞达标:750mg每日两次在92%患者中达标。
- 脑膜炎达标:500mg每日两次在85%患者中达标。
- 提出的临床敏感性折点为64 mg/L。
临床怎么用
- 临床可参考64 mg/L作为d-环丝氨酸的敏感性折点。
- 肺空洞感染可考虑750mg每日两次以达到目标暴露,但需警惕神经毒性。
- 脑膜炎患者500mg每日两次可达标,但仍需监测毒性。
局限性
- 未发现已发表的d-环丝氨酸药动学/药效学研究,需依赖新模型中空纤维系统实验。
- 达标剂量较高,可能神经毒性大,临床需权衡疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: d-cycloserine is used to treat multidrug-resistant tuberculosis. Its efficacy, contribution in combination therapy, and best clinical dose are unclear, also data on the d-cycloserine minimum inhibitory concentration (MIC) distributions is scant. METHODS: We performed a systematic search to identify pharmacokinetic and pharmacodynamic studies performed with d-cycloserine. We then performed a combined exposure-effect and dose fractionation study of d-cycloserine in the hollow fiber system model of tuberculosis (HFS-TB). In parallel, we identified d-cycloserine MICs in 415 clinical Mycobacterium tuberculosis (Mtb) isolates from patients. We utilized these results, including intracavitary concentrations, to identify the clinical dose that would be able to achieve or exceed target exposures in 10000 patients using Monte Carlo experiments (MCEs). RESULTS: There were no published d-cycloserine pharmacokinetics/pharmacodynamics studies identified. Therefore, we performed new HFS-TB experiments. Cyloserine killed 6.3 log10 colony-forming units (CFU)/mL extracellular bacilli over 28 days. Efficacy was driven by the percentage of time concentration persisted above MIC (%TMIC), with 1.0 log10 CFU/mL kill achieved by %TMIC = 30% (target exposure). The tentative epidemiological cutoff value with the Sensititre MYCOTB assay was 64 mg/L. In MCEs, 750 mg twice daily achieved target exposure in lung cavities of 92% of patients whereas 500 mg twice daily achieved target exposure in 85% of patients with meningitis. The proposed MCE-derived clinical susceptibility breakpoint at the proposed doses was 64 mg/L. CONCLUSIONS: Cycloserine is cidal against Mtb. The susceptibility breakpoint is 64 mg/L. However, the doses likely to achieve the cidality in patients are high, and could be neurotoxic.
引用
- Deshpande D, Alffenaar JC, Köser CU, et al. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Clin Infect Dis. 2018. PMID: 30496460. doi:10.1093/cid/ciy624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。